Next Article in Journal
Validation of Cadherin HAV6 Peptide in the Transient Modulation of the Blood-Brain Barrier for the Treatment of Brain Tumors
Previous Article in Journal
Assessing Drug Interaction and Pharmacokinetics of Loxoprofen in Mice Treated with CYP3A Modulators
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 11
Issue 9
10.3390/pharmaceutics11090480
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Development and Characterization of Eudragit®-Based Electrospun Nanofibrous Mats and Their Formulation into Nanofiber Tablets for the Modified Release of Furosemide

by
Marilena Vlachou
1,*,
Stefanos Kikionis
2,
Angeliki Siamidi
1,
Sotiria Kyriakou
1,
Andrew Tsotinis
3,
Efstathia Ioannou
2 and
Vassilios Roussis
2,*
1
Section of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece
2
Section of Pharmacognosy and Chemistry of Natural Products, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15771 Athens, Greece
3
Section of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2019, 11(9), 480; https://doi.org/10.3390/pharmaceutics11090480
Submission received: 5 August 2019 / Revised: 11 September 2019 / Accepted: 12 September 2019 / Published: 17 September 2019
Browse Figures
Versions Notes

Abstract

Furosemide, a chloride channel blocker ordinarily used as a high-ceiling or loop diuretic, is practically insoluble in water and dilute acids. Due to its acidic nature, furosemide is mostly absorbed in the stomach and in the upper small intestine. Efforts have focused on the development of sustained release systems of furosemide in order to improve the effectiveness of the drug, which exhibits poor aqueous solubility and poor permeability. Recently, electrospun nanofibrous drug delivery systems have emerged as promising alternative solid-dosage forms due to their advantages of high porosity, high surface to volume ratio, and high drug-loading efficacy. Herein, a number of nanofibrous mats composed of different types of Eudragit® polymers in various concentrations and combinations loaded with furosemide were designed, successfully electrospun, and characterized using SEM, FTIR, DSC, and TGA analyses. The nanofibrous nonwovens were formulated in nanofiber tablets and the release profile of furosemide from them was evaluated at pH 1.2 and 6.8 and compared to that of physical mixture matrix tablets of analogous composition as well as to that of a commercial formulation. It was found that the release of furosemide was compatible with the gastroretentive and slower intestinal release requirements with a well-defined absorption window, while some nanofiber formulations could act as furosemide carriers in emergency situations where a relatively fast onset of its action is required, as in the case of critically ill post-traumatic patients.
Keywords: furosemide; Eudragit®; electrospinning; nanofibers; tablets; modified release furosemide; Eudragit®; electrospinning; nanofibers; tablets; modified release
Graphical Abstract

Share and Cite

MDPI and ACS Style

Vlachou, M.; Kikionis, S.; Siamidi, A.; Kyriakou, S.; Tsotinis, A.; Ioannou, E.; Roussis, V. Development and Characterization of Eudragit®-Based Electrospun Nanofibrous Mats and Their Formulation into Nanofiber Tablets for the Modified Release of Furosemide. Pharmaceutics 2019, 11, 480. https://doi.org/10.3390/pharmaceutics11090480

AMA Style

Vlachou M, Kikionis S, Siamidi A, Kyriakou S, Tsotinis A, Ioannou E, Roussis V. Development and Characterization of Eudragit®-Based Electrospun Nanofibrous Mats and Their Formulation into Nanofiber Tablets for the Modified Release of Furosemide. Pharmaceutics. 2019; 11(9):480. https://doi.org/10.3390/pharmaceutics11090480

Chicago/Turabian Style

Vlachou, Marilena, Stefanos Kikionis, Angeliki Siamidi, Sotiria Kyriakou, Andrew Tsotinis, Efstathia Ioannou, and Vassilios Roussis. 2019. "Development and Characterization of Eudragit®-Based Electrospun Nanofibrous Mats and Their Formulation into Nanofiber Tablets for the Modified Release of Furosemide" Pharmaceutics 11, no. 9: 480. https://doi.org/10.3390/pharmaceutics11090480

APA Style

Vlachou, M., Kikionis, S., Siamidi, A., Kyriakou, S., Tsotinis, A., Ioannou, E., & Roussis, V. (2019). Development and Characterization of Eudragit®-Based Electrospun Nanofibrous Mats and Their Formulation into Nanofiber Tablets for the Modified Release of Furosemide. Pharmaceutics, 11(9), 480. https://doi.org/10.3390/pharmaceutics11090480

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop